Caricamento...
Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management
Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines display a superior advantage because the nasal mucosa is often the initial site of infection. Preclinical and clinical studies concerning intranasal immunization elicit high neutralizing antibody generation and mucosal IgA...
Salvato in:
| Pubblicato in: | Drug Discov Today |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Elsevier Ltd.
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8319039/ https://ncbi.nlm.nih.gov/pubmed/34332100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drudis.2021.07.021 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|